National Institute of Dental and Craniofacial Research; Notice of Meeting, 29770-29771 [05-10317]
Download as PDF
29770
Federal Register / Vol. 70, No. 99 / Tuesday, May 24, 2005 / Notices
the latent infected cells from the
uninfected cells; (2) even when
antiretroviral drugs are able to
completely suppress detectable HIV
replication, these latent infected cells
will remain and HIV can subsequently
complete the viral replication cycle to
produce more virus. Since proteosome
inhibitors can activate lytic replication
from latent infected cells, proteosome
inhibitors may lead to therapies in
which proteosome inhibitors are given
together with highly active antiretroviral
therapy in an effort to decrease or
eliminate the reservoir of latent infected
cells with hope of perhaps eventually
curing a patient of HIV infection.
Treatment of Human Viral Infections
(Imatinib)
Drs. Steven Zeichner and Vyjayanthi
Krishnan (NCI).
U.S. Provisional Application No. 60/
588,015 filed 13 Jul 2004 (DHHS
Reference No. E–281–2004/0–US–01).
Licensing Contact: Sally Hu; 301/435–
5606; hus@mail.nih.gov.
This application describes the
methods for treating or preventing a HIV
infection by the administration of ablkinase inhibitor called imatinib and its
derivatives. Several available agents can
inhibit HIV replication by targeting one
or another viral protein, such as the
viral reverse transcriptase, protease,
envelope fusion process, or integrase, or
by targeting the interaction of a viral
component with a host cell component,
for example the host cell viral receptor
or co-receptor. However, HIV can
readily become resistant to these drugs,
and new therapeutic approaches for HIV
infection are needed. The studies
described in the application show that
the expression of many host cell genes
changes in response to HIV replication,
and show that targeting one of these
changes with imatinib can inhibit viral
replication. Thus targeting the host cell,
and making the host cell less hospitable
to the virus can inhibit viral replication.
The application thus describes a new
agent that inhibits viral replication by
acting on the host cell, which may offer
new approaches to therapy for HIV
infection. These approaches may be less
likely to engender rapid resistance in
the virus to the therapy.
Treatment of Human Viral Infections
(Farnesyl Transferase Inhibitors)
Drs. Steven Zeichner and Vyjayanthi
Krishnan (NCI).
U.S. Provisional Application No. 60/
587,771 filed 13 Jul 2004 (DHHS
Reference No. E–282–2004/0–US–01).
Licensing Contact: Sally Hu; 301/435–
5606; hus@mail.nih.gov.
VerDate jul<14>2003
17:36 May 23, 2005
Jkt 205001
This application describes the
methods for treating or preventing an
HIV infection by the administration of
farnesyl transferase inhibitors such as
FTI277, L–744832, BMS214662,
R115777 and SCH66336. It has been
known that HIV, once it infects a cell,
integrates into the cellular genome and
can (1) rapidly undergo lytic infection,
or (2) lay dormant for a period of time
(latent infection). The existence of latent
infected cells poses a great challenge to
HIV therapy because (1) there are no
good existing means that can separate
the latent infected cells from the
uninfected cells; (2) even when
antiretroviral drugs are able to
completely suppress detectable HIV
replication, these latent infected cells
will remain and HIV can subsequently
complete the viral replication cycle to
produce more virus. Since farnesyl
transferase inhibitors can activate lytic
replication from latent infected cells by
modulating membrane-bound Ras-Rho
levels, farnesyl transferase inhibitors
may lead to therapies in which farnesyl
transferase inhibitor is given together
with highly active antiretroviral therapy
in an effort to decrease or eliminate the
reservoir of latent infected cells with
hope of perhaps eventually curing a
patient of HIV infection.
Dated: May 17, 2005.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 05–10316 Filed 5–23–05; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Frm 00056
Fmt 4703
Dated: May 16, 2005.
LaVerne Y. Stringfield,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–10327 Filed 5–23–05; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Dental and
Craniofacial Research; Notice of
Meeting
BILLING CODE 4140–01–P
PO 00000
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel
Review of Research Projects (Cooperative
Agreements) U01s.
Date: May 27, 2005.
Time: 9 a.m. to 11 a.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Valerie L. Prenger, PhD,
Health Scientist Administrator, Review
Branch, Room 7214, Division of Extramural
Affairs, National Heart, Lung, and Blood
Institute, 6701 Rockledge Drive, MSC 7924,
Bethesda, MD 20892–7924, (301) 435–0270,
prengerv@nhlbi.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Sfmt 4703
Notice is hereby given of a Conference
on Research Training Initiatives,
sponsored by the National Institute of
Dental and Craniofacial Research
(NIDCR).
The conference will be open to the
public as indicated below, with
attendance limited to space available.
This meeting will also be made
available by video cast at
https://videocast.nih.gov/.
Conference Name: Research Training
Initiatives.
Date: June 9, 2005.
Open: 8:30 a.m. to 5 p.m.
Agenda: The conference will focus on
a variety of issues relating to research
training. A significant portion of the
meeting will be devoted to discussion of
training of both clinician scientists and
basic scientists, from building a
pipeline, through undergraduate,
graduate and postgraduate research
training culminating in bridging to
scientific independence.
E:\FR\FM\24MYN1.SGM
24MYN1
Federal Register / Vol. 70, No. 99 / Tuesday, May 24, 2005 / Notices
Additional presentations and
discussion will focus on models for
successful programs at various
educational and career development
stages, definition of what constitutes
success, the role of mentoring, academic
environment, K–12 science education
and related topics.
Speakers and plenary discussion
panel members include representatives
from the NIH, the National Academics
of Science, the National Science
Foundation and the Howard Hughes
Medical Institute.
Place: National Institutes of Health,
Natcher Building (Building 45),
Conference Rm. 1–2, 4500 Center Drive,
Bethesda, MD 20892.
Public Comment: Individuals who
wish to provide public comment (oral or
written) should contact the Acting
Deputy Director, NIDCR, Dr. Henning
Birkedal Hansen, by telephone at (301)
496–9469 or e-mail at Henning.BirkedalHansen@nih.gov no later than May 25,
2005.
Contact Person: Henning BirkedalHansen, Ph.D., Acting Deputy Director,
National Institute of Dental and
Craniofacial Research, 31 Center Drive,
Room 2C39, Bethesda, MD 20892, (301)
496–9469.
Information is also available on the
Institute’s home page: https://
www.nidcr.nih.gov/about, where an
agenda and any additional information
for the meeting will be posted when
available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify Ms. Rita Lehr at (301) 496–9469
prior to the meeting.
Dated: May 18, 2005.
Henning Birkedal-Hansen,
Acting Deputy Director, National Institute of
Dental and Craniofacial Research.
[FR Doc. 05–10317 Filed 5–23–05; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Dental &
Craniofacial Research; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
VerDate jul<14>2003
17:36 May 23, 2005
Jkt 205001
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Dental and Craniofacial Research Special
Emphasis Panel, 05–52, Review R21s.
Date: June 20, 2005.
Time: 1:45 p.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Natcher Building, 45 Center Drive, Bethesda,
MD 20892, (Telephone Conference Call).
Contact Person: H. George Hausch, PhD,
Acting Director, 45 Center Drive, Natcher
Building, Rm. 4AN44F, National Institutes of
Health, Bethesda, MD 20892, (301) 594–2904,
george_hausch@nih.gov.
Name of Committee: National Institute of
Dental and Craniofacial Research Special
Emphasis Panel, 05–78, Review R13.
Date: June 23, 2005.
Time: 2 p.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Natcher Building, 45 Center Drive, Bethesda,
MD 20892, (Telephone Conference Call).
Contact Person: Mary Kelly, Scientific
Review Specialist, National Institute of
Dental & Craniofacial Res., 45 Center Drive,
Natcher Bldg., RM 4AN38J, Bethesda, MD
20892–6402, (301) 594–4809,
marylkelly@nih.gov.
Name of Committee: National Institute of
Dental and Craniofacial Research Special
Emphasis Panel, 05–76, Review R13.
Date: June 28, 2005.
Time: 2 p.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Natcher Building, 45 Center Drive, Bethesda,
MD 20892, (Telephone Conference Call).
Contact Person: Mary Kelly, Scientific
Review Specialist, National Institute of
Dental & Craniofacial Res., 45 Center Drive,
Natcher Bldg., RM 4AN38J, Bethesda, MD
20892–6402, (301) 594–4809,
marylkelly@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.121, Oral Diseases and
Disorders Research, National Institutes of
Health, HHS)
Dated: May 16, 2005.
LaVerne Y. Stringfield,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–10318 Filed 5–23–05; 8:45 am]
BILLING CODE 4140–01–M
PO 00000
Frm 00057
Fmt 4703
Sfmt 4703
29771
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Dental &
Craniofacial Research; Notice of
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of a meeting of the
Board of Scientific Counselors, National
Institute of Dental and Craniofacial
Research.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting. The meeting
will be closed to the public as indicated
below in accordance with the provisions
set forth in section 552b(c)(6), Title 5
U.S.C., as amended for the review,
discussion, and evaluation of individual
intramural programs and projects
conducted by the National Institute of
Dental & Craniofacial Research,
including consideration of personnel
qualifications and performance, and the
competence of individual investigators,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Board of Scientific
Counselors, National Institute of Dental and
Craniofacial Research, Review of the
Craniofacial & Skeletal Diseases Branch,
NIDCR.
Date: May 25–27, 2005.
Closed: May 25, 2005, 7 p.m. to 8:30 p.m.
Agenda: To review and evaluate personal
qualifications and performance, and
competence of individual investigators.
Place: National Institutes of Health,
Building 30, 30 Convent Drive, Conference
Room 117, Bethesda, MD 20892.
Open: May 26, 2005, 8:30 a.m. to 11:40
a.m.
Agenda: Investigator presentations.
Place: National Institutes of Health,
Building 30, 30 Convent Drive, Conference
Room 117, Bethesda, MD 20892.
Closed: May 26, 2005, 11:40 a.m. to 1 p.m.
Agenda: To review and evaluate personal
qualifications and performance, and
competence of individual investigators.
Place: National Institutes of Health,
Building 30, 30 Convent Drive, Conference
Room 117, Bethesda, MD 20892.
Open: May 26, 2005, 1 p..m. to 6 p.m.
Agenda: Investigator presentations, Lab
Tour, Poster Presentation.
Place: National Institutes of Health,
Building 30, 30 Convent Drive, Conference
Room 117, Bethesda, MD 20892.
Closed: May 27, 2005, 8:30 a.m. to 3 p.m.
E:\FR\FM\24MYN1.SGM
24MYN1
Agencies
[Federal Register Volume 70, Number 99 (Tuesday, May 24, 2005)]
[Notices]
[Pages 29770-29771]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-10317]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Dental and Craniofacial Research; Notice of
Meeting
Notice is hereby given of a Conference on Research Training
Initiatives, sponsored by the National Institute of Dental and
Craniofacial Research (NIDCR).
The conference will be open to the public as indicated below, with
attendance limited to space available. This meeting will also be made
available by video cast at https://videocast.nih. gov/.
Conference Name: Research Training Initiatives.
Date: June 9, 2005.
Open: 8:30 a.m. to 5 p.m.
Agenda: The conference will focus on a variety of issues relating
to research training. A significant portion of the meeting will be
devoted to discussion of training of both clinician scientists and
basic scientists, from building a pipeline, through undergraduate,
graduate and postgraduate research training culminating in bridging to
scientific independence.
[[Page 29771]]
Additional presentations and discussion will focus on models for
successful programs at various educational and career development
stages, definition of what constitutes success, the role of mentoring,
academic environment, K-12 science education and related topics.
Speakers and plenary discussion panel members include
representatives from the NIH, the National Academics of Science, the
National Science Foundation and the Howard Hughes Medical Institute.
Place: National Institutes of Health, Natcher Building (Building
45), Conference Rm. 1-2, 4500 Center Drive, Bethesda, MD 20892.
Public Comment: Individuals who wish to provide public comment
(oral or written) should contact the Acting Deputy Director, NIDCR, Dr.
Henning Birkedal Hansen, by telephone at (301) 496-9469 or e-mail at
Henning.Birkedal-Hansen@nih.gov no later than May 25, 2005.
Contact Person: Henning Birkedal-Hansen, Ph.D., Acting Deputy
Director, National Institute of Dental and Craniofacial Research, 31
Center Drive, Room 2C39, Bethesda, MD 20892, (301) 496-9469.
Information is also available on the Institute's home page: https://
www.nidcr.nih.gov/about, where an agenda and any additional information
for the meeting will be posted when available.
Individuals who plan to attend and need special assistance, such as
sign language interpretation or other reasonable accommodations, should
notify Ms. Rita Lehr at (301) 496-9469 prior to the meeting.
Dated: May 18, 2005.
Henning Birkedal-Hansen,
Acting Deputy Director, National Institute of Dental and Craniofacial
Research.
[FR Doc. 05-10317 Filed 5-23-05; 8:45 am]
BILLING CODE 4140-01-M